On June 10, Merck announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing license application for its Class 1 innovative drug Pimicotinib for adult patients with giant tendon sheath tumors requiring systematic treatment. Zhou Hong, global executive vice president of Merck Healthcare and head of the Chinese and international market, said that the company is simultaneously proceeding with the submission of listing license applications to the US FDA and plans to file in other markets one after another.

On June 10, Merck announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing license application for its Class 1 innovative drug Pimicotinib for adult patients with giant tendon sheath tumors requiring systematic treatment. Zhou Hong, global executive vice president of Merck Healthcare and head of the Chinese and international market, said that the company is simultaneously proceeding with the submission of listing license applications to the US FDA and plans to file in other markets one after another.